Clinical trials: Anophthalmia, active
Eye Abnormalities
Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations
Ocular morphogenesis is a complex process starting as early as the 4th week of embryonic life, involving interactions between varioustissues of different origin and conserved genes.
- Trial name
- OrganoEye (NCT06408701)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Microphthalmia, Coloboma
Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children
The investigators are inviting families to take part in a research study that will help us better understand the physical characteristics associated with children who have Microphthalmia, Anophthalmia, and Coloboma (MAC) and how…
- Conditions
- Microphthalmia, Coloboma, Anophthalmia
- Trial name
- MAGIC (NCT06293560)
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Anophthalmia, Microphthalmia
National Cohort on Congenital Defects of the Eye
Congenital malformations of the eye comprise various developmental defects including microphthalmia, anophthalmia, aniridia, and anterior segment anomalies (such as Peters and Axenfeld-Rieger anomalies).
- Conditions
- Anophthalmia, Microphthalmia, Aniridia, Anterior Segment Dysgenesis 6, Peters Anomaly Subtype
- Trial name
- RaDiCoACOEIL (NCT05954403)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Carcinoma, Pancreatic Ductal, Prognosis
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1).
- Trial name
- PACsign (NCT05475366)
- Testing
- Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies)
- Where
- 7 sites in France
- Volunteers
- 79 people
- Sponsor
- Institut Curie
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Metastatic PDAC, HER2-positive Status
A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy
Pancreatic cancer is an extremely high-mortality malignancy. The chemotherapy regimen of gemcitabine combined with nab-paclitaxel (GEM-NABP) serves as one of the first-line standard therapies for metastatic pancreatic cancer.
- Trial name
- NCT07176702
- Testing
- HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC)
To confirm the safety of combining oral fecal microbiota transplantation (FMT) with gemcitabine and nab-paclitaxel chemotherapy as first line treatment in patients with unresectable or metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CHASe-PDAC (NCT06393400)
- Testing
- Fecal Microbiota Transplantation, PEG3350, Gemcitabine
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- John Lenehan
Coloboma, Anophthalmia
Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)
Background: Uveal coloboma is a condition where the eye does not form normally. It occurs early in the fetus s development during pregnancy. It can lead to different kinds of eye problems, including blindness.
- Conditions
- Coloboma, Anophthalmia, Microphthalmia
- Trial name
- NCT01778543
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Eye Institute (NEI)
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie